Cart
sales@molnova.com
MK-0429
CAS No. 227963-15-7
MK-0429( MK0429 )
Catalog No. M13624 CAS No. 227963-15-7
MK-0429 is a potent, selective, orally-active nonpeptide αvβ3 integrin inhibitor with IC50 of 0.08 nM in SPAV3 assay.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 50MG | 1674 | In Stock |
|
| 100MG | 2502 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMK-0429
-
NoteResearch use only, not for human use.
-
Brief DescriptionMK-0429 is a potent, selective, orally-active nonpeptide αvβ3 integrin inhibitor with IC50 of 0.08 nM in SPAV3 assay.
-
DescriptionMK-0429 is a potent, selective, orally-active nonpeptide αvβ3 integrin inhibitor with IC50 of 0.08 nM in SPAV3 assay; displays approximately 100-fold selectivity for αvβ3 over αvβ5 (IC50=10 nM), and no significant activity for the fibrinogen receptor αIIBβ3 (IC50>30 uM); shows activity in different animal models of bone turnover and has potentiation for the prevention and treatment of osteoporosis; also reduces melanoma metastasis both in vitro and in vivo.Prostate Cancer Phase 1 Discontinued.
-
In Vitro——
-
In VivoMK-0429 (100 or 300 mg/kg, p.o., twice daily b.i.d., 2 weeks) reduces metastatic tumor colony formation and area in the lungs. MK-0429 is safe and efficacious in significantly decreasing melanoma metastasis in the lungs. Animal Model:B6D2F1 hybrid female mice Dosage:100 or 300 mg/kg Administration:P.o., twice daily (b.i.d.), 2 weeks Result:MK-0429 at 100 and 300 mg/kg reduced the number of metastatic tumor colonies by 64 and 57%, respectively, and the high dose also reduced the tumor area by 60% as compared to the vehicle.
-
SynonymsMK0429
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
RecptorIntegrin
-
Research AreaCancer
-
IndicationProstate Cancer
Chemical Information
-
CAS Number227963-15-7
-
Formula Weight439.51
-
Molecular FormulaC23H29N5O4
-
Purity>98% (HPLC)
-
SolubilityDMSO : 250 mg/mL 568.82 mM
-
SMILESO=C(O)C[C@@H](C1=CC=C(OC)N=C1)N2CCN(CCCC3=NC4=C(CCCN4)C=C3)C2=O
-
Chemical Name(S)-3-(6-methoxypyridin-3-yl)-3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Hutchinson JH, et al. J Med Chem. 2003 Oct 23;46(22):4790-8.
2. Pickarski M, et al. Oncol Rep. 2015 Jun;33(6):2737-45.
3. Zhou X, et al. Pharmacol Res Perspect. 2017 Oct;5(5).
molnova catalog
related products
-
Echistatin, α1 isofo...
Potent irreversible αVβ3 integrin antagonist (Ki = 0.27 nM). Disrupts attachment of osteoclasts to bone and inhibits bone reabsorption (IC50 = 0.1 nM). Prevents ADP-induced platelet aggregation via inhibition of glycoprotein IIb/IIIa (GpIIb/IIIa, αIIbβ3) receptors (IC50 = 30 nM) in vitro.
-
Abrilumab
Abrilumab (MEDI-7183) is a fully human monoclonal antibody against α4β7 that inhibits the α4β7 integrin and can be used to study inflammatory bowel disease and ulcerative colitis.
-
Lifitegrast
A potent LFA-1/ICAM-1 antagonist with IC50 of 9 nM in HuT78 cells; exhibits good in vitro safety profile and low potency on CYP3A4, CYP2C9 and hERG.
